Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy
Cancers · 21.02.2025 · 17 (5) · 731
DOI: 10.3390/cancers17050731 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 21.02.2025. Verfasst von Bence Gergely und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, Hungary, GINOP, Hungarian Research Network.
Abstract (Originalsprache)
Background/Objectives: Monoclonal antibody therapies for HER2-positive tumors frequently encounter resistance, requiring alternative treatment strategies. This study investigates the use of natural killer (NK) cells expressing HER2-specific chimeric antigen receptor (CAR) to address this issue. CAR NK cells have several benefits over CAR T cells: they are less likely to cause severe side effects such as cytokine release syndrome and neurotoxicity, can be sourced from various origins, and do not trigger Graft versus Host Disease, making them ideal for “off-the-shelf” applications.
Methods
We have generated NK-92 cell lines expressing first, second and third-generation HER2-specific CARs with CD28 and/or 41BB costimulatory domains using a retroviral transduction system, followed by FACS sorting and expansion to obtain pure HER2-CAR NK-92 cell products for functional benchmarking.
Results
In vitro tests showed that these CAR NK cells were effective against both trastuzumab-sensitive (CD44−) and -resistant (CD44+) tumors in monolayer cultures. However, in three-dimensional spheroid models and in vivo xenografts, they were less effective against CD44+ trastuzumab-resistant tumors.
Conclusions
This reduced efficacy highlights the significant role of the tumor microenvironment, particularly the extracellular matrix, in hindering the therapeutic potential of CAR NK cells. Despite the promising in vitro performance of CAR NK cells, this study emphasizes the need for improved strategies to enhance their penetration and effectiveness in resistant tumors: optimizing CAR constructs and devising methods to overcome extracellular matrix barriers are crucial for advancing CAR NK cell therapies in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- HUN-REN-UD Cell Biology and Signaling Research Group, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary.
ORCID-Profile: Bence Gergely, István Rebenku, György Vereb, Árpád Szöőr
Förderung
- National Research, Development and Innovation Office, Hungary
- GINOP
- Hungarian Research Network
- University of Debrecen Program for Scientific Publication
- János Bolyai Research Scholarship
- New National Excellence Program of the Ministry for Innovation and Technology, Hungary
- National Research, Development, and Innovation Office, Hungary
- European Union and the European Regional Development
Zitieren
APA
Gergely, B., Vereb, M. A., Rebenku, I., Vereb, G., & Szöőr, Á. (2025). Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy. Cancers, 17(5), 731. https://doi.org/10.3390/cancers17050731
Vancouver
Gergely B, Vereb MA, Rebenku I, Vereb G, Szöőr Á. Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy. Cancers. 2025;17(5):731. doi:10.3390/cancers17050731
BibTeX
@article{Gergely2025,
author = {Gergely, Bence and Vereb, Márk A and Rebenku, István and Vereb, György and Szöőr, Árpád},
title = {Targeting HER2-Positive Solid Tumors with CAR NK Cells: CD44 Expression Is a Critical Modulator of HER2-Specific CAR NK Cell Efficacy},
journal = {Cancers},
year = {2025},
volume = {17},
number = {5},
pages = {731},
doi = {10.3390/cancers17050731}
}
EUVIMED